DEFA14A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of

the Securities Exchange Act of 1934

(Amendment No.    )

Filed by the Registrant  ☒

Filed by a party other than the Registrant  ☐

Check the appropriate box:

 

  Preliminary Proxy Statement
  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
  Definitive Proxy Statement
  Definitive Additional Materials
  Soliciting Material under §240.14a-12

TURNING POINT THERAPEUTICS, INC.

 

 

(Name of Registrant as Specified In Its Charter)

 

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

  No fee required
  Fee paid previously with preliminary materials
  Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 


 

 

LOGO

 

P.O. BOX 8016, CARY, NC 27512-9903

 

Turning Point Therapeutics, Inc.

Important Notice Regarding the Availability

of Proxy Materials

 

Stockholders Meeting to be held on

June 16, 2022

For Stockholders of record as of April 18, 2022

 

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

 

To view the proxy materials, and to obtain directions to attend the meeting, go to: www.proxydocs.com/TPTX

 

To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

 

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.

 

LOGO

 

 

LOGO  

For a convenient way to view proxy materials and VOTE go to

www.proxydocs.com/TPTX

  LOGO
 

Have the 12 digit control number located in the shaded box above available

when you access the website and follow the instructions.

 

 

 

If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before June 06, 2022.

 

To order paper materials, use one of the following methods.

 

 

LOGO

 

INTERNET www.investorelections.com/TPTX

        

 

LOGO

 

TELEPHONE

(866) 648-8133

        

 

LOGO

 

* E-MAIL

paper@investorelections.com

        When requesting via the Internet or telephone you will need the 12 digit

        control number located in the shaded box above.

   

* If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located above) in the subject line. No other requests, instructions or other inquiries should be included with your e-mail requesting material.

 

 

Turning Point Therapeutics, Inc.

 

Meeting Type: Annual Meeting of Stockholders

Date:    Thursday, June 16, 2022

Time:   8:30 AM, Pacific Time

Place:   Annual Meeting to be held live via the internet - please visit

              www.proxydocs.com/TPTX for more details.

 

You must register to attend the meeting online and/or participate at www.proxydocs.com/TPTX

 

SEE REVERSE FOR FULL AGENDA

 

 


Turning Point Therapeutics, Inc.

Annual Meeting of Stockholders

The Board of Directors recommends that you vote “FOR” all of the nominees for director listed below and “FOR” Proposals 2 and 3.

 

PROPOSAL

 

1.

To elect two nominees for Class III director to serve for three-year terms until the 2025 Annual Meeting of Stockholders.

1.01 Mark J. Alles

1.02 Barbara W. Bodem

 

2.

To approve, on an advisory basis, the compensation of our named executive officers as disclosed in the proxy statement.

 

3.

To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2022.

 

4.

To conduct any other business properly brought before the meeting.